Cart
sales@molnova.com
Pritumumab
CAS No. 499212-74-7
Pritumumab( —— )
Catalog No. M37296 CAS No. 499212-74-7
Pritumumab (ACA 11) is a natural human IgG1 κ antibody that can be used to study glioblastoma and brain tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 505 | Get Quote |
|
| 5MG | 749 | Get Quote |
|
| 10MG | 1123 | Get Quote |
|
| 25MG | 1835 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePritumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPritumumab (ACA 11) is a natural human IgG1 κ antibody that can be used to study glioblastoma and brain tumors.
-
DescriptionPritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number499212-74-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017.
molnova catalog
related products
-
Hexadecanedioic acid
Hexadecanedioic acid is a common saturated fatty acid found in animals plants and microorganisms. It has antitumor activity.
-
ELOVL1-IN-1
ELOVL1-IN-1 is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).
-
Melanotan I
Melanotan-I has the amino acid sequence of Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val and a molecular weight of 1647.4 Dalton.
